Sensitive and Specific Serodiagnosis of Lyme Disease by Enzyme-Linked Immunosorbent Assay with a Peptide Based on an Immunodominant Conserved Region of Borrelia burgdorferi VlsE
Fang Ting Liang,Allen C. Steere,Adriana Marques,Barbara J. B. Johnson,James N. Miller,Mario T. Philipp +5 more
TLDR
This simple, sensitive, specific, and precise ELISA may contribute to alleviate some of the remaining problems in Lyme disease serodiagnosis.Abstract:
VlsE, the variable surface antigen of Borrelia burgdorferi, contains an immunodominant conserved region named IR6. In the present study, the diagnostic performance of a peptide enzyme-linked immunosorbent assay (ELISA) based on a 26-mer synthetic peptide (C6) with the IR6 sequence was explored. Sensitivity was assessed with serum samples (n = 210) collected from patients with clinically defined Lyme disease at the acute (early localized or early disseminated disease), convalescent, or late disease phase. The sensitivities for acute-, convalescent-, and late-phase specimens were 74% (29 of 39), 85 to 90% (34 of 40 to 35 of 39), and 100% (59 of 59), respectively. Serum specimens from early neuroborreliosis patients were 95% positive (19 of 20), and those from an additional group of patients with posttreatment Lyme disease syndrome yielded a sensitivity of 62% (8 of 13). To assess the specificity of the peptide ELISA, 77 serum samples from patients with other spirochetal or chronic infections, autoimmune diseases, or neurologic diseases and 99 serum specimens from hospitalized patients in an area where Lyme disease is not endemic were examined. Only two potential false positives from the hospitalized patients were found, and the overall specificity was 99% (174 of 176). Precision, which was assessed with a panel of positive and negative serum specimens arranged in blinded duplicates, was 100%. Four serum samples with very high anti-OspA antibody titers obtained from four monkeys given the OspA vaccine did not react with the C6 peptide. This simple, sensitive, specific, and precise ELISA may contribute to alleviate some of the remaining problems in Lyme disease serodiagnosis. Because of its synthetic peptide base, it will be inexpensive to manufacture. It also will be applicable to serum specimens from OspA-vaccinated subjects.read more
Citations
More filters
Journal ArticleDOI
Diagnosis of Lyme Borreliosis
TL;DR: PCR should not be used as the sole laboratory modality to support a clinical diagnosis of extracutaneous LB, and PCR positivity in seronegative patients suspected of having late manifestations of LB most likely represents a false-positive result.
Journal ArticleDOI
Lyme borreliosis in Europe and North America.
Joseph Piesman,Lise Gern +1 more
TL;DR: The biology of the aetiologic agents, as well as the clinical aspects, diagnosis and treatment of this disease on both continents, and the transmission dynamics of the spirochete are reviewed in an attempt to compare and contrast Lyme borreliosis in Europe and North America.
Journal ArticleDOI
Serodiagnosis of Lyme Disease by Kinetic Enzyme-Linked Immunosorbent Assay Using Recombinant VlsE1 or Peptide Antigens of Borrelia burgdorferi Compared with 2-Tiered Testing Using Whole-Cell Lysates
Rendi Murphree Bacon,Brad J. Biggerstaff,Martin E. Schriefer,Robert D. Gilmore,Mario T. Philipp,Allen C. Steere,Gary P. Wormser,Adriana Marques,Barbara J. B. Johnson +8 more
TL;DR: The overall sensitivities for detecting IgG antibody to rVlsE1 or C6 in samples from patients with diverse manifestations of Lyme disease were equivalent to that of 2-tiered testing and the sensitivities of the in parallel tests and 2- tiered testing were high and statistically equivalent.
Journal ArticleDOI
Microbiological and serological diagnosis of Lyme borreliosis
TL;DR: In Europe, Lyme borreliosis is caused by Borrelia burgdorferi sensu stricto, B. garinii and the recently described species B. spielmanii, and the heterogeneity of the causative agents must be considered.
Journal ArticleDOI
Prospective Study of Serologic Tests for Lyme Disease
TL;DR: Except in patients with erythema migrans, both test systems were sensitive for support of the diagnosis of Lyme disease, and with current methods, 2-tier testing was associated with slightly better specificity.
References
More filters
Journal Article
Medical progress. Lyme disease
TL;DR: Mise a jour des connaissances sur la maladie, due a Borrelia burgdorferi, transmise par tiques, role des souris dans la survie de B. b.
Journal ArticleDOI
Antigenic Variation in Lyme Disease Borreliae by Promiscuous Recombination of VMP-like Sequence Cassettes
TL;DR: An elaborate genetic system in the Lyme disease spirochete Borrelia burgdorferi that promotes extensive antigenic variation of a surface-exposed lipoprotein, VlsE, could potentially produce millions of antigenic variants in the mammalian host.
Journal ArticleDOI
Western Blotting in the Serodiagnosis of Lyme Disease
TL;DR: Western blotting can be used to increase the specificity of serologic testing in Lyme disease.
Journal ArticleDOI
Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant
Allen C. Steere,Vijay K. Sikand,François Meurice,Dennis Parenti,Erol Fikrig,Robert T. Schoen,John Nowakowski,Christopher H. Schmid,Sabine Laukamp,Charles Buscarino,David S. Krause +10 more
TL;DR: Three injections of vaccine prevented most definite cases of Lyme disease or asymptomatic B. burgdorferi infection in 10,936 subjects in areas of the United States in which Lyme disease is endemic.